Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.5086 | 0.5086 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.2711 | 0.5 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.5086 | 0.5051 |
Echinococcus multilocularis | lamin | 0.0033 | 0.5086 | 1 |
Onchocerca volvulus | 0.0033 | 0.5086 | 0.5 | |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.2711 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.5086 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.2711 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.4906 | 0.4906 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.5086 | 0.5051 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.2711 | 0.5 |
Echinococcus multilocularis | musashi | 0.0033 | 0.5086 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.2711 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.5086 | 1 |
Onchocerca volvulus | 0.0033 | 0.5086 | 0.5 | |
Brugia malayi | cytoplasmic intermediate filament protein | 0.0017 | 0.0522 | 0.0456 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.5086 | 0.5086 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.2711 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.2711 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.5086 | 0.5086 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.5335 | 0.5335 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0033 | 0.5335 | 0.5303 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0522 | 0.0522 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.2711 | 0.5 |
Brugia malayi | hypothetical protein | 0.0025 | 0.2711 | 0.266 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.5086 | 1 |
Echinococcus granulosus | lamin | 0.0033 | 0.5086 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.2711 | 0.2711 |
Schistosoma mansoni | hypothetical protein | 0.0033 | 0.5335 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 1.2589 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 9.285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 21.3313 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488991] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.